Revolutionizing Osteoarthritis Treatment
Pioneering a novel, long-acting injectable therapeutic for lasting pain relief and inflammation reduction.
Our Mission
At Calosyn Pharma, our mission is to transform the lives of those suffering from osteoarthritis through groundbreaking therapies. By focusing on the development and commercialization of CAL-05CR, a sustained-release injectable treatment, we aim to offer long-lasting pain relief and target the root cause of osteoarthritis with minimal side effects.
Guided by Expertise
With over 20 years of dedicated research, Dr. David Waddell, Calosyn’s founder, has been at the forefront of osteoarthritis treatment. His extensive studies on verapamil as a therapeutic for osteoarthritis have led to groundbreaking results, including three IRB studies demonstrating significant pain reduction in patients.
What is Osteoarthritis?
Osteoarthritis is a degenerative condition characterized by the breakdown of cartilage in joints, leading to pain, inflammation, and eventually, the need for joint replacement. Affecting over 30 million Americans, osteoarthritis is becoming increasingly prevalent due to aging, obesity, and sports-related injuries.
Introducing
CAL-05CR
Calosyn’s lead product, CAL-05CR, is a game-changing treatment for moderate to severe osteoarthritis pain. This injectable therapy combines verapamil with a sustained-release formula offering long-lasting relief, directly targeting the root cause of osteoarthritis.
Provides sustained therapeutic effects in the joint.
Designed to offer pain relief without the side effects encountered with other treatments.
Demonstrates positive effects in osteoarthritis models by blocking calcium ion channels.
